LONGBIO-B

1779
56.3005.30% ( -3.150 )
Delay Closed: Nov 16, 16:08:11

Overview

LONGBIO-B (1779)

LongBio Pharma (Suzhou) Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, manufacture, and commercialization of biopharma...

Open
59.000
High
59.000
Low
53.950
Prev. Close
59.450
Volume
72.50K
Turnover
4.02M
Avg Price
55.418
Bid/Ask Ratio
16.13%
Amplitude
8.49%
52wk High
165.900
Volume Ratio
0.68
Turnover Ratio
0.11%
52wk Low
43.200
HK Mkt Cap
3.83B
Market CapHKD
4.30B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-3.26
EPSDynamic
-4.07
EPSStatic
--
BVPS
17.00
P/B
3.31
HK Shares
67.97M
Dividend YieldTTM
--
DividendTTM
--
Shares
76.32M
Min lot size
50
Currency
HKD

Daily Events

  1. Nov, 16

    Longbio-B opened at HK$59.00, slid to HK$54.00 by 10:48 in the morning session and recovered to close at HK$57.55, down 3.2% on the day with an intraday range of more than 9%, as no fresh catalyst emerged and the stock kept digesting the 12%-15% single-day swings seen since late October and last week's 4.21% low-volume rebound. The fundamentals remain pre-revenue: Q2 2026 EPS was -HK$1.2563, a 26.21% wider loss year on year, net loss -HK$77.85 million, 50.84% deeper, and operating loss 78.98% larger, with ROE at -23.92%, PB 3.38x and PE -17.65x. The price sits below its MA20 of HK$58.28 and roughly 36% under the MA60 of HK$90.68, down 56.34% year to date and 65.31% below the 52-week high of HK$165.90 set on 29 June, while still 33.22% above the 3 November low of HK$43.20. Though turnover was only 0.10% on HK$3.63 million of value, thin liquidity amplifies the daily range.

  2. Nov, 12

    LongBio-B (1779.HK) spiked then faded, touching HK$66.60 at 11:01 BJ, up more than 7% from the HK$62.00 previous close, before momentum drained and the stock slid to HK$60.95 at 15:59 and closed at HK$61.00, down 1.6% on 93,250 shares worth HK$5.89 million, with the HK$63.19 average price sitting above the close. That pattern extends a whipsaw stretch: single-session moves of +13% and -11% alternated last week even as the stock gained 10.8% over the week, and it only set a 52-week low in late October, so the price has rebounded off that floor but has given back most of this week's advance. Q2 2026 net loss of HK$77.85 million widened 50.8% year on year and the operating loss of HK$77.26 million widened 79.0%, losses expanding alongside the volatility, while the 100% transfusion-avoidance result for LP-005 in its Phase II PNH trial remains the main catalyst. Though the float is thin, so a few million Hong Kong dollars of turnover can amplify double-digit swings.

  3. Nov, 11

    LONGBIO-B gapped up 6.6% to HK$65.00 at the open, then surrendered the gain to a 58.25 morning-session low before recovering to close at HK$61.60, up 1.07% on just HK$5.22 million turnover and a 0.13% turnover rate — a thin float amplifying two-way swings rather than fresh repricing. The shares have moved 43% and 12% in single sessions recently and have rebounded more than 42% off the HK$43.20 52-week low set on 3 November; they now sit marginally above the 20-day MA of HK$60.99 but far below the 60-day MA of HK$93.34, 62.87% under the HK$165.90 52-week high and down 53.26% year-to-date. Fundamentals have not turned: Q2 2026 net loss widened 50.84% year-on-year to HK$77.85 million, EPS -HK$1.2563, PE -18.89x, PB 3.62x, with no revenue disclosed, while LP-005's 100% transfusion avoidance in its Phase II PNH trial remains the pipeline narrative. Though the widening loss and empty top line leave the bounce looking like oversold repair.

  4. Nov, 10

    Longbio-B rose 6.8% to HK$60.95, extending a rebound off its HK$43.2 52-week low on Nov 3 as interest in complement inhibitors stayed warm, with Phase II topline data for LP-005 in PNH and discussion that the US$10 billion complement market is only a starting point both still circulating. The session opened lower at HK$57.30, dipped to HK$57.10 and spiked to HK$61.35 by 09:32 BJ, then flattened near HK$59 before grinding higher through the afternoon to close at HK$60.95, close to the intraday high. Volume was just 39,600 shares worth HK$2.38 million, a 0.06% turnover rate, so thin liquidity amplified the range. Fundamentals remain pre-revenue: the Q2 2026 net loss was HK$77.85 million, 50.8% wider year on year, with an operating loss of HK$77.26 million, EPS of -HK$1.26 and PB at 3.58x. The stock is still down 53.8% YTD and trades below its MA20 of HK$62.40 and MA60 of HK$94.37, 63.3% under the HK$165.9 June high, while the thin tape keeps moves headline-driven.

  5. Nov, 9

    LONGBIO-B staged a spike-and-fade session, opening at HK$57.00 and surging to HK$62.40 at 13:44 BJ—about 9.6% above the prior close of HK$56.95—before erasing the gain to close at HK$57.05, up 0.18%, on HK$14.2 million turnover and a 0.35% turnover rate. The intraday pulse followed recent Phase II PNH data for LP-005 showing 100% transfusion avoidance and rising attention on the complement-inhibitor space, extending the stock's volatile run after a 10.8% weekly gain. Fundamentals remain loss-making: Q2 2026 net loss was HK$77.85 million, 50.8% wider year on year, operating loss was HK$77.26 million, 79.0% wider, and EPS was -HK$1.2563, leaving little earnings support for the rebound. The stock is still 65.6% below its 52-week high of HK$165.9, down 56.7% YTD, and below its MA20 of HK$63.84 and MA60 of HK$95.36. Though the 10.8% weekly advance leaves room for profit-taking and turnover was only HK$14.2 million, the close near the day's low keeps focus on whether the recent data-driven interest can be sustained.

News